Aliases & Classifications for Pigmentation Disease

MalaCards integrated aliases for Pigmentation Disease:

Name: Pigmentation Disease 12 15 17
Pigmentation Disorders 56 74
Skin Pigmentation Disorder 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10123
ICD9CM 36 709.09
ICD10 34 L81 L81.8

Summaries for Pigmentation Disease

Disease Ontology : 12 A skin disease that is characterized by discoloration of the skin.

MalaCards based summary : Pigmentation Disease, also known as pigmentation disorders, is related to reticulate acropigmentation of kitamura and dowling-degos disease, and has symptoms including muscle weakness, polydipsia and pruritus. An important gene associated with Pigmentation Disease is IKBKG (Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma), and among its related pathways/superpathways are NRF2 pathway and Glucose / Energy Metabolism. The drugs Fluticasone and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and eye, and related phenotypes are growth/size/body region and integument

Related Diseases for Pigmentation Disease

Diseases related to Pigmentation Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 reticulate acropigmentation of kitamura 31.3 ADAR POFUT1
2 dowling-degos disease 30.9 ADAR POFUT1 POGLUT1
3 neonatal jaundice 30.9 G6PD SLCO1B1 UGT1A1
4 hypomelanosis of ito 11.3
5 vitiligo-associated multiple autoimmune disease susceptibility 1 11.1
6 dyschromatosis symmetrica hereditaria 10.7
7 dyschromatosis universalis hereditaria 10.7
8 hypopigmentation of eyelid 10.7
9 legius syndrome 10.7
10 crigler-najjar syndrome, type i 10.3 UGT1A1 UGT1A6
11 anemia, nonspherocytic hemolytic, due to g6pd deficiency 10.3 G6PD IKBKG
12 descending colon cancer 10.2 UGT1A1 UGT1A6
13 dihydropyrimidine dehydrogenase deficiency 10.2 UGT1A1 UGT1A6
14 pyruvate kinase deficiency of red cells 10.2 G6PD PKM
15 bilirubin, serum level of, quantitative trait locus 1 10.2 UGT1A1 UGT1A6 UGT1A8
16 crigler-najjar syndrome, type ii 10.2 UGT1A1 UGT1A6 UGT1A8
17 leber congenital amaurosis 4 10.2 UGT1A1 UGT1A6 UGT1A8
18 dowling-degos disease 1 10.1 FGFR3 IKBKG
19 inherited metabolic disorder 10.1 INS UGT1A1 UGT1A6
20 sickle cell anemia 10.1 G6PD UGT1A1 UGT1A6
21 lipodystrophy, familial partial, type 2 10.1 AGPAT2 INS
22 berardinelli-seip congenital lipodystrophy 10.0 AGPAT2 BSCL2
23 lipodystrophy, congenital generalized, type 2 10.0 AGPAT2 BSCL2
24 spastic paraplegia 17, autosomal dominant 10.0 AGPAT2 BSCL2
25 irinotecan toxicity 10.0 SLCO1B1 UGT1A1
26 lipodystrophy, familial partial, type 3 10.0 AGPAT2 BSCL2
27 acetaminophen metabolism 9.9 UGT1A1 UGT1A6
28 kernicterus 9.9 G6PD PKM UGT1A1 UGT1A6
29 large intestine cancer 9.9 INS PKM UGT1A1 UGT1A6
30 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.9 AGPAT2 BSCL2 INS
31 complete generalized lipodystrophy 9.9 AGPAT2 BSCL2 INS
32 lipodystrophy, congenital generalized, type 3 9.9 AGPAT2 BSCL2
33 lipodystrophy, congenital generalized, type 1 9.9 AGPAT2 BSCL2 INS
34 familial partial lipodystrophy 9.9 AGPAT2 BSCL2 INS
35 acquired generalized lipodystrophy 9.9 AGPAT2 BSCL2 INS
36 congenital generalized lipodystrophy 9.8 AGPAT2 BSCL2
37 glucosephosphate dehydrogenase deficiency 9.8 G6PD SLCO1B1 UGT1A1
38 lipodystrophy, congenital generalized, type 4 9.8 AGPAT2 BSCL2
39 neutrophil migration 9.8
40 hyperpigmentation with or without hypopigmentation, familial progressive 9.6
41 lentigines 9.6
42 hutchinson-gilford progeria syndrome 9.6
43 spastic paraplegia 23, autosomal recessive 9.6
44 ichthyosis prematurity syndrome 9.6
45 oculocutaneous albinism 9.6
46 albinism 9.6
47 spastic paraparesis 9.6
48 nevus of ota 9.6
49 gilbert syndrome 9.5 G6PD SLCO1B1 UGT1A1 UGT1A6 UGT1A8
50 bilirubin metabolic disorder 9.5 G6PD PKM SLCO1B1 UGT1A1 UGT1A6

Graphical network of the top 20 diseases related to Pigmentation Disease:



Diseases related to Pigmentation Disease

Symptoms & Phenotypes for Pigmentation Disease

UMLS symptoms related to Pigmentation Disease:


muscle weakness, polydipsia, pruritus, exanthema

MGI Mouse Phenotypes related to Pigmentation Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.91 ADAR AGPAT2 BSCL2 FGFR3 G6PD IKBKG
2 integument MP:0010771 9.7 ADAR AGPAT2 BSCL2 FGFR3 IKBKG INS
3 liver/biliary system MP:0005370 9.43 ADAR AGPAT2 BSCL2 IKBKG INS POGLUT1
4 mortality/aging MP:0010768 9.32 ADAR AGPAT2 BSCL2 FGFR3 G6PD IKBKG

Drugs & Therapeutics for Pigmentation Disease

Drugs for Pigmentation Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4,Not Applicable 90566-53-3 62924
2
Fluorouracil Approved Phase 4 51-21-8 3385
3
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable,Early Phase 1 22916-47-8 4189
5
Hydroquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 123-31-9 785
6
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
8
Pimecrolimus Approved, Investigational Phase 4,Phase 2 137071-32-0 17753757 6447131
9
Azelaic acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 123-99-9 2266
10
Metformin Approved Phase 4 657-24-9 14219 4091
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
12
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1197-18-8 5526
13
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
14
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
15
Prilocaine Approved Phase 4,Not Applicable 721-50-6 4906
16
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
17
Tetracaine Approved, Vet_approved Phase 4,Not Applicable 94-24-6 5411
18
Desonide Approved, Investigational Phase 4 638-94-8 5311066
19
Nicotinamide Approved, Investigational Phase 4,Early Phase 1,Not Applicable 98-92-0 936
20
Iron Approved, Experimental Phase 4,Phase 1,Phase 2 7439-89-6, 15438-31-0 27284 23925
21
Zinc Approved, Investigational Phase 4,Phase 2,Phase 1 7440-66-6 32051
22
Zinc oxide Approved Phase 4,Phase 2 1314-13-2
23
Titanium dioxide Approved Phase 4 13463-67-7
24
Avobenzone Approved, Investigational Phase 4 70356-09-1
25
Oxybenzone Approved, Investigational Phase 4 131-57-7 4632
26
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
27
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 69-72-7 338
28
Glycolic acid Approved, Investigational Phase 4,Not Applicable,Early Phase 1 79-14-1 757
29
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2 67-73-2 6215
30
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
31
Benzoyl peroxide Approved Phase 4 94-36-0 7187
32
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
33
Aminolevulinic acid Approved Phase 4 106-60-5 137
34
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99011-02-6 57469
35
Everolimus Approved Phase 4,Phase 2 159351-69-6 70789204 6442177
36
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 46835353 5284616 6436030
37
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
38
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 302-79-4 444795 5538
39
Vitamin C Approved, Nutraceutical Phase 4,Not Applicable 50-81-7 54670067 5785
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Early Phase 1,Not Applicable 59-30-3 6037
41
Niacin Approved, Investigational, Nutraceutical Phase 4,Early Phase 1,Not Applicable 59-67-6 938
42
Benzophenone Experimental Phase 4 119-61-9 3102
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
45 Autonomic Agents Phase 4,Phase 2,Not Applicable
46 Anti-Allergic Agents Phase 4,Not Applicable
47 Bronchodilator Agents Phase 4,Not Applicable
48 Respiratory System Agents Phase 4,Phase 1,Phase 2,Not Applicable
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Anti-Asthmatic Agents Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 331)
# Name Status NCT ID Phase Drugs
1 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
2 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Unknown status NCT01640678 Phase 4
3 Punchgrafting Techniques for Vitiligo Unknown status NCT01377077 Phase 4
4 Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation Unknown status NCT02904564 Phase 4
5 Efficacy & Safety of Clindamycin and Tretinoin in Acne Unknown status NCT01111994 Phase 4 Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
6 Clinical Trial of Hydroquinone Versus Miconazol in Melasma Unknown status NCT01661556 Phase 4 Miconazole;Hydroquinone
7 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
8 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
9 Azelaic Acid Versus Hydroquinone in Melasma Unknown status NCT00927771 Phase 4 azelaic acid gel;hydroquinone cream
10 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
11 A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. Completed NCT00293163 Phase 4
12 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Completed NCT02458417 Phase 4
13 Fractional Laser Assisted Delivery of Anesthetics III Completed NCT02938286 Phase 4 AHES
14 Fractional Laser Assisted Delivery of Anesthetics Completed NCT02246179 Phase 4 AHES;EMLA cream
15 Fractional Laser Assisted Delivery of Anesthetics IIIb Completed NCT03279757 Phase 4 AHES 5 minutes;AHES 15 minutes;AHES 25 minutes;LTC 5 minutes;LTC 15 minutes;LTC 25 minutes
16 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
17 Ascorbic Acid Versus Diode Laser in the Treatment of Gingival Hyperpigmentation Completed NCT03252418 Phase 4 Ascorbic Acid 500 MG
18 Evaluation of an Herbal-Based De-Pigmenting System Completed NCT02138539 Phase 4 Hydroquinone
19 Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation Completed NCT01542138 Phase 4 Desonide;Niacinamide;Placebo
20 Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Completed NCT01149876 Phase 4 Tretinoin cream 0.05
21 NB-UVB and PUVA Vitiligo Study Completed NCT01732965 Phase 4
22 Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Completed NCT01695356 Phase 4 290-400 nm sunscreen;290-800 nm sunscreen
23 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
24 Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women Completed NCT00616239 Phase 4 20-30% Salicylic Acid peels to the right side of the face;20-30% Salicylic Acid peels to the left side of the face
25 Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Completed NCT00500162 Phase 4
26 Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Completed NCT00472966 Phase 4 Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
27 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4 Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
28 Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid Completed NCT00166192 Phase 4
29 The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color Completed NCT03402893 Phase 4 ONEXTON Topical Gel
30 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH) Completed NCT01038869 Phase 4 Azelaic acid
31 Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease Completed NCT00549601 Phase 4 Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day);Rivastigmine patch (9.5 mg/day);Rivastigmine capsules (6 mg to 12 mg/day)
32 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
33 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
34 Oral Tranexamic Acid and Laser for Treatment of Melasma Recruiting NCT03686787 Phase 4 Tranexamic Acid
35 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Recruiting NCT03199664 Phase 4
36 Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome Recruiting NCT03781050 Phase 4 Rapamycin
37 Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Not yet recruiting NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
38 Different Dermatological Approaches the Treatment of Melasma Not yet recruiting NCT03923062 Phase 4
39 Tranexamic Acid vs. Combination With Fractional Carbon Dioxide Laser in Melasma Not yet recruiting NCT03899233 Phase 4 Tranexamic acid intradermal microinjections
40 USE THE SYSTEMIC METFORMIN IN MELASMA Not yet recruiting NCT03475524 Phase 4 MetFORMIN 1000 Mg Oral Tablet;Placebos;Trichloroacetic Acid Peeling;MetFORMIN 500 Mg Oral Tablet
41 Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid Not yet recruiting NCT03153852 Phase 4 Modified Jessner's solution;Glycolic acid;Trichloroacetic acid
42 Fractional Laser Assisted Topical Anesthesia Terminated NCT02548533 Phase 4 AHES;EMLA cream
43 Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser Terminated NCT00863278 Phase 4 Kligman's Trio
44 Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma Terminated NCT00669071 Phase 4 Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%;Cetaphil® Moisturizing Cream as Inactive Control
45 Topical Bimatoprost Solution 0.03%in Stable Vitiligo Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
46 Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
47 Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma Unknown status NCT00848458 Phase 2, Phase 3
48 Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol Unknown status NCT00525395 Phase 3
49 A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Unknown status NCT02156427 Phase 3
50 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion

Search NIH Clinical Center for Pigmentation Disease

Genetic Tests for Pigmentation Disease

Anatomical Context for Pigmentation Disease

MalaCards organs/tissues related to Pigmentation Disease:

42
Skin, Testes, Eye, Breast, Pancreas, Bone, Lymph Node

Publications for Pigmentation Disease

Articles related to Pigmentation Disease:

(show all 23)
# Title Authors Year
1
Low-fluenced erbium:yttrium-aluminium-garnet laser treatment in combination with broadband light pretreatment for various pigmentation disorders in Asian patients. ( 30825265 )
2019
2
Pigmentation Disorders in the Elderly. ( 30637685 )
2019
3
Pathological modelling of pigmentation disorders associated with Hutchinson-Gilford Progeria Syndrome (HGPS) revealed an impaired melanogenesis pathway in iPS-derived melanocytes. ( 29904107 )
2018
4
Classification of non-tumorous skin pigmentation disorders using voting based probabilistic linear discriminant analysis. ( 29909227 )
2018
5
Pigmentation Disorders: Diagnosis and Management. ( 29431372 )
2017
6
Pigmentation disorders. ( 26738250 )
2015
7
Hair pigmentation disorders or 50 years of German-Polish alliance for study on a severe side effect of chemotherapy: Kostanecki's legacy. ( 25279945 )
2015
8
Pigmentation disorders: hyperpigmentation and hypopigmentation. ( 24314378 )
2014
9
Biology and genetics of oculocutaneous albinism and vitiligo - common pigmentation disorders in southern Africa. ( 24300644 )
2013
10
The etiology and molecular genetics of human pigmentation disorders. ( 23799582 )
2013
11
Mosaic pigmentation disorders and associated syndromes. ( 22150346 )
2012
12
Pigmentation disorders. ( 21789987 )
2011
13
Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. ( 20103661 )
2010
14
Common pigmentation disorders. ( 19178061 )
2009
15
[Factors affecting melanogenesis and methods used for identification of pigmentation disorders]. ( 18942345 )
2008
16
Pigmentation disorders in skin of color: the role of natural substances. ( 19064237 )
2008
17
The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. ( 18369335 )
2008
18
Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. ( 17176301 )
2006
19
Epidemiologic and etiologic features of pigmentation disorders observed during consultation at the Dermatology Center of Abidjan, Ivory Coast. ( 16187956 )
2005
20
Racial differences in the treatment of pigmentation disorders in outpatient settings: analysis of US national practice data. ( 15764036 )
2004
21
Spotlight on spotted mice: a review of white spotting mouse mutants and associated human pigmentation disorders. ( 15140066 )
2004
22
Melanin pigmentation disorders of the skin and oral mucosa. ( 1860110 )
1991
23
Pigmentation disorders. ( 3378370 )
1988

Variations for Pigmentation Disease

Expression for Pigmentation Disease

Search GEO for disease gene expression data for Pigmentation Disease.

Pathways for Pigmentation Disease

GO Terms for Pigmentation Disease

Cellular components related to Pigmentation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.35 AGPAT2 BSCL2 UGT1A1 UGT1A6 UGT1A8
2 endoplasmic reticulum GO:0005783 9.23 AGPAT2 BSCL2 FGFR3 POFUT1 POGLUT1 UGT1A1

Biological processes related to Pigmentation Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 glucose metabolic process GO:0006006 9.54 G6PD INS PKM
2 acute-phase response GO:0006953 9.49 INS UGT1A1
3 negative regulation of lipid catabolic process GO:0050995 9.48 BSCL2 INS
4 regulation of Notch signaling pathway GO:0008593 9.46 POFUT1 POGLUT1
5 cellular glucuronidation GO:0052695 9.43 UGT1A1 UGT1A6
6 retinoic acid metabolic process GO:0042573 9.4 UGT1A1 UGT1A8
7 flavone metabolic process GO:0051552 9.32 UGT1A1 UGT1A8
8 negative regulation of fatty acid metabolic process GO:0045922 9.26 INS UGT1A8
9 negative regulation of steroid metabolic process GO:0045939 9.16 UGT1A1 UGT1A8
10 xenobiotic glucuronidation GO:0052697 9.13 UGT1A1 UGT1A6 UGT1A8
11 flavonoid glucuronidation GO:0052696 8.8 UGT1A1 UGT1A6 UGT1A8

Molecular functions related to Pigmentation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.97 AGPAT2 FGFR3 PKM POFUT1 POGLUT1 UGT1A1
2 identical protein binding GO:0042802 9.88 FGFR3 G6PD IKBKG INS PKM
3 protein homodimerization activity GO:0042803 9.8 G6PD IKBKG UGT1A1 UGT1A6 UGT1A8
4 protein heterodimerization activity GO:0046982 9.76 IKBKG UGT1A1 UGT1A6 UGT1A8
5 transferase activity, transferring hexosyl groups GO:0016758 9.5 UGT1A1 UGT1A6 UGT1A8
6 steroid binding GO:0005496 9.43 UGT1A1 UGT1A8
7 glucuronosyltransferase activity GO:0015020 9.43 UGT1A1 UGT1A6 UGT1A8
8 retinoic acid binding GO:0001972 9.33 UGT1A1 UGT1A6 UGT1A8
9 UDP-glycosyltransferase activity GO:0008194 9.13 UGT1A1 UGT1A6 UGT1A8
10 transferase activity, transferring glycosyl groups GO:0016757 9.02 POFUT1 POGLUT1 UGT1A1 UGT1A6 UGT1A8

Sources for Pigmentation Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....